prescription

处方
  • 文章类型: Journal Article
    背景:上呼吸道感染(URI)的抗生素处方高达50%是不合适的。减少不必要的抗生素处方的临床决策支持(CDS)系统已被实施到电子健康记录中。但是提供商对它们的使用受到限制。
    目的:作为委托协议,我们采用了经过验证的电子健康记录集成临床预测规则(iCPR)基于CDS的注册护士(RN)干预措施,包括分诊以识别低视力URI患者,然后进行CDS指导的RN访视。它于2022年2月实施,作为纽约4个学术卫生系统内43个初级和紧急护理实践的随机对照阶梯式楔形试验。威斯康星州,还有犹他州.虽然问题出现时得到了务实的解决,需要对实施障碍进行系统评估,以更好地理解和解决这些障碍。
    方法:我们进行了回顾性案例研究,从专家访谈中收集有关临床工作流程和分诊模板使用的定量和定性数据,研究调查,与实践人员进行例行检查,和图表回顾实施iCPR干预措施的第一年。在更新的CFIR(实施研究综合框架)的指导下,我们描述了在动态护理中对RN实施URIiCPR干预的初始障碍.CFIR结构被编码为缺失,中性,弱,或强大的执行因素。
    结果:在所有实施领域中发现了障碍。最强的障碍是在外部环境中发现的,随着这些因素的不断下降,影响了内部环境。由COVID-19驱动的当地条件是最强大的障碍之一,影响执业工作人员的态度,并最终促进以工作人员变化为特征的工作基础设施,RN短缺和营业额,和相互竞争的责任。有关RN实践范围的政策和法律因州和机构对这些法律的适用而异,其中一些允许RNs有更多的临床自主权。这需要在每个研究地点采用不同的研究程序来满足实践要求。增加创新的复杂性。同样,体制政策导致了与现有分诊的不同程度的兼容性,房间,和文档工作流。有限的可用资源加剧了这些工作流冲突,以及任选参与的实施气氛,很少有参与激励措施,因此,与其他临床职责相比,相对优先级较低。
    结论:在医疗保健系统之间和内部,患者摄入和分诊的工作流程存在显著差异.即使在相对简单的临床工作流程中,工作流程和文化差异明显影响了干预采用。本研究的收获可以应用于现有工作流程中的新的和创新的CDS工具的其他RN委托协议实现,以支持集成和改进吸收。在实施全系统临床护理干预时,必须考虑该州文化和工作流程的可变性,卫生系统,实践,和个人水平。
    背景:ClinicalTrials.govNCT04255303;https://clinicaltrials.gov/ct2/show/NCT04255303。
    BACKGROUND: Up to 50% of antibiotic prescriptions for upper respiratory infections (URIs) are inappropriate. Clinical decision support (CDS) systems to mitigate unnecessary antibiotic prescriptions have been implemented into electronic health records, but their use by providers has been limited.
    OBJECTIVE: As a delegation protocol, we adapted a validated electronic health record-integrated clinical prediction rule (iCPR) CDS-based intervention for registered nurses (RNs), consisting of triage to identify patients with low-acuity URI followed by CDS-guided RN visits. It was implemented in February 2022 as a randomized controlled stepped-wedge trial in 43 primary and urgent care practices within 4 academic health systems in New York, Wisconsin, and Utah. While issues were pragmatically addressed as they arose, a systematic assessment of the barriers to implementation is needed to better understand and address these barriers.
    METHODS: We performed a retrospective case study, collecting quantitative and qualitative data regarding clinical workflows and triage-template use from expert interviews, study surveys, routine check-ins with practice personnel, and chart reviews over the first year of implementation of the iCPR intervention. Guided by the updated CFIR (Consolidated Framework for Implementation Research), we characterized the initial barriers to implementing a URI iCPR intervention for RNs in ambulatory care. CFIR constructs were coded as missing, neutral, weak, or strong implementation factors.
    RESULTS: Barriers were identified within all implementation domains. The strongest barriers were found in the outer setting, with those factors trickling down to impact the inner setting. Local conditions driven by COVID-19 served as one of the strongest barriers, impacting attitudes among practice staff and ultimately contributing to a work infrastructure characterized by staff changes, RN shortages and turnover, and competing responsibilities. Policies and laws regarding scope of practice of RNs varied by state and institutional application of those laws, with some allowing more clinical autonomy for RNs. This necessitated different study procedures at each study site to meet practice requirements, increasing innovation complexity. Similarly, institutional policies led to varying levels of compatibility with existing triage, rooming, and documentation workflows. These workflow conflicts were compounded by limited available resources, as well as an implementation climate of optional participation, few participation incentives, and thus low relative priority compared to other clinical duties.
    CONCLUSIONS: Both between and within health care systems, significant variability existed in workflows for patient intake and triage. Even in a relatively straightforward clinical workflow, workflow and cultural differences appreciably impacted intervention adoption. Takeaways from this study can be applied to other RN delegation protocol implementations of new and innovative CDS tools within existing workflows to support integration and improve uptake. When implementing a system-wide clinical care intervention, considerations must be made for variability in culture and workflows at the state, health system, practice, and individual levels.
    BACKGROUND: ClinicalTrials.gov NCT04255303; https://clinicaltrials.gov/ct2/show/NCT04255303.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    洛莫司汀是儿科神经肿瘤学中常用的口服化疗药物。我们报道了一个15岁以前健康的男孩,他被错误地开了洛莫司汀而不是扁桃体炎的抗生素。随后,他患有长期的骨髓发育不全,中性粒细胞减少症和普遍存在的出血。摄入洛莫司汀后约7周开始骨髓再生。到目前为止,还没有发现其他永久性器官损伤。口服化疗药物只能由专家开处方,并以尽可能小的包装尺寸分配。
    Lomustine is an oral chemotherapy drug commonly used in pediatric neuro-oncology. We report on a 15-year-old formerly healthy boy, who was erroneously prescribed lomustine instead of an antibiotic for tonsillitis. He subsequently suffered from prolonged bone marrow aplasia with secondary fever in neutropenia and ubiquitous bleeding. Bone marrow regeneration started approximately 7 weeks after lomustine intake. No other permanent organ damage has been detected thus far. Oral chemotherapeutic drugs should only be prescribed by experts and dispensed in the smallest possible pack size.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    关于使用激素避孕和失眠之间可能关联的证据有限。我们将嵌套病例对照设计应用于全国范围的女性样本,15-49岁,来自国家医疗保健登记册,以表征使用激素避孕与失眠发生之间的关联。共有294,356名激素避孕使用者和294,356名非激素避孕使用者。在随访两年的1,148,969人年中,出现了11,105例新的失眠病例。在34岁或以下的参与者中出现了激素避孕与失眠的所有显着关联,如果只关注三级护理数据,在15-19岁的人群中。屈螺酮和炔雌醇的固定组合以及环丙孕酮和炔雌醇的固定组合的使用者失眠的几率显着降低,而与非使用者相比,左炔诺孕酮释放宫内治疗以及阴道环伴依托孕酮和炔雌醇的使用者失眠的几率显著增加。我们的发现表明,用于激素避孕的不同产品可能与失眠的发生存在差异。
    Evidence is limited concerning possible associations between the use of hormonal contraception and insomnia. We applied the nested case-control design on a nationwide sample of women, aged 15-49 years, derived from national health care registries to characterize the association between the use of hormonal contraception and the occurrence of insomnia. There were altogether 294,356 users and 294,356 non-users of hormonal contraception. 11,105 new cases of insomnia emerged among the 1,148,969 person-years of the follow-up period of two years. All the significant associations of hormonal contraception with insomnia emerged among the participants aged 34 years or younger, and if only the tertiary care data was concerned, among the those aged 15-19 years. The users of the fixed combination of drospirenone and ethinylestradiol as well as that of cyproterone and ethinylestradiol had significantly decreased odds for insomnia, whereas the users levonorgestrel-releasing intrauterine devise as well as those of vaginal ring with etonogestrel and ethinylestradiol had significantly increased odds for insomnia as compared with non-users. Our findings suggest that different products prescribed for hormonal contraception may be differentially associated with the occurrence of insomnia.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:尽管有研究观察了皮肤科医生对心理皮肤病学的态度,很少有人强调药剂师对这些情况的态度。
    目的:学习知识,药剂师对皮肤科患者精神药物处方的态度和做法。
    方法:这项横断面分析包括来自孟买的80名药剂师,印度。我们使用面试官管理的问卷来收集药剂师关于他们的人口统计学的信息,皮肤病患者的精神药物,有关心理状况的知识和分配这些药物的舒适度。
    结果:在我们的研究中,37名(46%)药剂师接受皮肤科医生的精神药物处方;然而,24(30%)不舒服地分配它们。60名(75%)药剂师认为只有精神科医生才应该开精神药物,37名(46%)认为他们有权拒绝配药;其中,15人(19%)实际上拒绝给患者服药。药剂师不同意“精神状态与医疗条件有关”的说法,更有可能阻止皮肤科医生的精神处方(29%对11%,P=0.04)。具有五年以上经验的药剂师更有可能拒绝分配药物(比值比:5.14,95%置信区间:1.02,25.83;P=0.047)。
    结论:我们没有孟买所有药剂师的名单;因此,没有采样框架可以应用。
    结论:药剂师会对医生的处方发表评论,劝阻某些药物,甚至根据他们的个人意见拒绝分发。由于它们是患者在医生和药物之间的最后一站,它们的包含(除了皮肤科医生,精神病学家和心理学家)在综合意识中,培训和护理计划将提高患有精神疾病的患者的护理质量。
    BACKGROUND: Though studies have looked at the attitudes of dermatologists towards psychodermatology, few have highlighted the attitudes of pharmacists towards these conditions.
    OBJECTIVE: To study the knowledge, attitudes and practices of pharmacists towards the prescription of psychotropic medications to dermatology patients.
    METHODS: This cross-sectional analysis included 80 pharmacists from Mumbai, India. We used an interviewer-administered questionnaire to collect information from pharmacists on their demographics, psychotropic medications in dermatological patients, knowledge about psychocutaneous conditions and comfort about dispensing these medications.
    RESULTS: In our study, 37 (46%) of pharmacists received prescriptions of psychotropic drugs from dermatologists; however, 24 (30%) were not comfortable dispensing them. Sixty (75%) pharmacists felt that only psychiatrists should prescribe psychotropic drugs and 37 (46%) felt that they had a right to refuse to dispense prescribed medication; of these, 15 (19%) had actually refused to give medications to patients. Pharmacists who disagreed with the statement that \'the state of mind is associated with medical conditions\', were more likely to discourage psychotropic prescription from dermatologists (29% vs 11%, P = 0.04). Pharmacists with experience of more than five years were significantly more likely to refuse to dispense medications (odds ratio: 5.14, 95% confidence interval: 1.02, 25.83; P = 0.047).
    CONCLUSIONS: We did not have a list of all pharmacists in Mumbai; thus, no sampling frame could be applied.
    CONCLUSIONS: Pharmacists do comment on doctors\' prescriptions, discourage certain medications and even refuse to dispense them based on their personal opinions. Since they are the last stop for patients between the doctor and the medication, their inclusion (in addition to dermatologists, psychiatrists and psychologists) in integrated awareness, training and care programs would improve the quality of care of patients with psychocutaneous disorders.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    为了应对1型糖尿病的技术创新进展缓慢,一些患者创造了不受管制的自己动手的人造胰腺系统(DIYAPS)。然而,无论是在英国(英国)还是在国际上,几乎完全缺乏具体指导-法律,监管,或道德-对于照顾DIYAPS用户的临床医生。他们的职业义务的不确定性导致他们对与患者讨论DIYAPS持谨慎态度,更不用说推荐或处方了。在这篇文章中,我们认为,这种方法有可能破坏信任和透明度。通过分析英国监管机构-总医学委员会的专业指导,我们证明其中的任何内容都不应被解释为阻止临床医生发起有关DIYAPS的讨论。此外,在某些情况下,这可能需要临床医生这样做。我们还认为,该指南并不排除临床医生开具此类未经批准的医疗设备。
    In response to slow progress regarding technological innovations to manage type 1 diabetes, some patients have created unregulated do-it-yourself artificial pancreas systems (DIY APS). Yet both in the United Kingdom (UK) and internationally, there is an almost complete lack of specific guidance - legal, regulatory, or ethical - for clinicians caring for DIY APS users. Uncertainty regarding their professional obligations has led to them being cautious about discussing DIY APS with patients, let alone recommending or prescribing them. In this article, we argue that this approach threatens to undermine trust and transparency. Analysing the professional guidance from the UK regulator - the General Medical Council - we demonstrate that nothing within it ought to be interpreted as precluding clinicians from initiating discussions about DIY APS. Moreover, in some circumstances, it may require that clinicians do so. We also argue that the guidance does not preclude clinicians from prescribing such unapproved medical devices.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    BACKGROUND: In addition to their potent lipid-lowering action, statins may modulate inflammation. However, data on statin use and the risk of inflammatory bowel diseases [IBD] have been inconsistent.
    METHODS: We searched the Nationwide Swedish Patient Register [inpatient and non-primary outpatient care] to identify adults diagnosed with Crohn\'s disease [CD, n = 7637] or ulcerative colitis [UC, n = 15 652] from 2006 to 2014. Each case was matched to 10 general population controls [n = 232 890]. Data on dispensed statin prescriptions were extracted from the Prescribed Drug Register. Conditional logistic regression models estimated odds ratios [ORs] for risk of IBD according to statin exposure while controlling for potential confounders, including indications for statin therapy.
    RESULTS: In multivariable adjusted models, compared with no statin use, any statin use was associated with a lower risk of CD (OR = 0.71; 95% confidence interval [CI], 0.63-0.79), but not UC [OR = 1.03; 95% CI, 0.96-1.11]. The lowest OR for CD was seen for current statin use [OR = 0.67; 95% CI, 0.60-0.75]. For CD, the lowest category of cumulative statin dose [31-325 defined daily dose, DDD] was associated with an OR of 0.73 [95% CI, 0.61-0.88] and the highest category [>1500 DDD] with an OR of 0.66 [95% CI, 0.55-0.80], ptrend = 0.10. For UC, the lowest and highest dose categories yielded ORs of 1.12 [95% CI, 1.00-1.25] and 0.99 [95% CI, 0.88-1.13], respectively, ptrend = 0.13.
    CONCLUSIONS: Statin use was associated with a lower risk of CD, but not of UC. The association with CD risk appeared strongest for current statin use. Our findings suggest that statin use may influence the development of CD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    To demonstrate a process of calculating the maximum potential morphine milligram equivalent daily dose (MEDD) based on the prescription Sig for use in quality improvement initiatives. To calculate an opioid prescription\'s maximum potential Sig-MEDD, we developed SQL code to determine a prescription\'s maximum units/day using discrete field data and text-parsing in the prescription instructions. We validated the derived units/day calculation using 3000 Sigs, then compared the Sig-MEDD calculation against the Epic-MEDD calculator. Of the 101 782 outpatient opioid prescriptions ordered over 1 year, 80% used discrete-field Sigs, 7% used free-text Sigs, and 3% used both types. We determined units/day and calculated a Sig-MEDD for 98.3% of all the prescriptions, 99.99% of discrete-Sig prescriptions, and 81.5% of free-text-Sig prescriptions. Analyzing opioid prescription Sigs to determine a maximum potential Sig-MEDD provides greater insight into a patient\'s risk for opioid exposure.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    Cancer patients are often prescribed antidepressants, but little data is available about whether the type and dose are similar to prescriptions to patients with other chronic diseases. This study compared the prescription practices of antidepressants to cancer and non-cancer inpatients at a major Australian tertiary hospital and assessed side effects and potential drug-drug interactions.
    Inpatients diagnosed with cancer within the past 12 months and prescribed antidepressants were age and gender matched to inpatients with other chronic disease conditions. Data from 75 cancer and 75 non-cancer inpatients were extracted.
    Antidepressants were prescribed to cancer and non-cancer patients, respectively, for the treatment of depression (n = 50 vs n = 59), other mental health problems (n = 8 vs n = 11, p < 0.67) or unspecified reasons (n = 17 vs n = 5, p < 0.02). Mirtazapine (n = 11/75) was most commonly prescribed to cancer patients followed by duloxetine (n = 9/75). Desvenlafaxine (n = 15/75) was prescribed most commonly to non-cancer inpatients, followed by mirtazapine (n = 11/75). Four cancer patients and three non-cancer patients had documented adverse side effects from antidepressants. About one-third of cancer patients (n = 23/75) and about a quarter of non-cancer patients (n = 18/75) were prescribed other medicines with the potential for drug-drug interactions with antidepressants.
    Antidepressants were prescribed for a range of indications in all patients, but more commonly for unspecified reasons among the cancer patients. Future prospective studies that monitor antidepressant prescribing to cancer patients should ascertain details of the indication, pathways to prescription and differences in type, dose or schedule depending on prescribing medical practitioner.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    Although there has been a sizeable empirical literature measuring the effect of job precariousness on the mental health of workers the debate is still open, and understanding the true nature of such relationship has important policy implications. In this paper, we investigate the impact of precarious employment on mental health using a unique, very large data set that matches information on job contracts for over 2.7 million employees in Italy followed over the years 2007-2011, with their psychotropic medication prescription. We examine the causal effects of temporary contracts, their duration and the number of contract changes during the year on the probability of having one or more prescriptions for medication to treat mental health problems. To this end, we estimate a dynamic Probit model, and deal with the potential endogeneity of regressors by adopting an instrumental variables approach. As instruments, we use firm-level probabilities of being a temporary worker as well as other firm-level variables that do not depend on the mental illness status of the workers. Our results show that the probability of psychotropic medication prescription is higher for workers under temporary job contracts. More days of work under temporary contract as well as frequent changes in temporary contract significantly increase the probability of developing mental health problems that need to be medically treated. We also find that moving from permanent to temporary employment increases mental illness; symmetrically, although with a smaller effect in absolute value, moving from temporary to permanent employment tends to reduce it. Policy interventions aimed at increasing the flexibility of the labour market through an increase of temporary contracts should also take into account the social and economic cost of these reforms, in terms of psychological wellbeing of employees.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号